SCHEMBL12269735

SCHEMBL12269735

Cn1cncc1C#Cc1n[nH]c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.46
▸ HSP90AA1 P07900 1/20 0.42
▸ ATM Q13315 2/20 0.41
▸ UBE2N P61088 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.37
▸ GAA P10253 2/20 0.37
▸ PDPK1 O15530 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ IDO1 P14902 2/20 0.36
▸ LRRK2 Q5S007 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ ALPL P05186 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TTK P33981 1/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ ITK Q08881 1/20 0.35
▸ PIKFYVE Q9Y2I7 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MAP3K14 Q99558 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12619743 0.82 AXL (0.44) TDP1HSP90AA1ATMUBE2NKDM4E
SCHEMBL12619759 0.82 AXL (0.44) TDP1HSP90AA1ATMUBE2NKDM4E
SCHEMBL12619738 0.79 TDP1 (0.40) TDP1HSP90AA1ATMUBE2NPIKFYVE
SCHEMBL12269662 0.78 TDP1 (0.38) TDP1HSP90AA1KDM4EGAACYP3A4
SCHEMBL13839354 0.75 LRRK2 (0.40) TDP1HSP90AA1PDPK1LRRK2ITK
SCHEMBL12269661 0.75 MAP2K4 (0.42) TDP1KDM4EGAAALDH1A1HPGD
SCHEMBL13839356 0.75 LRRK2 (0.42) TDP1KDM4ELRRK2ALDH1A1ITK
SCHEMBL13839355 0.72 TDP1 (0.36) TDP1HSP90AA1ATMUBE2NKDM4E
SCHEMBL17887974 0.72 KDM4E (0.48) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL12318032 0.71 IDO1 (0.50) KDM4EGAAPDPK1CYP3A4IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212961-A1 Pyrazole Derivatives as Kinase Inhibitors BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2011-09-01 — — US disclosed
US-7951832-B2 Pyrazole derivatives as kinase inhibitors BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2011-05-31 — — US disclosed
US-20090124621-A1 PYRAZOLE DERIVATIVES AS KINASE INHIBITORS BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2009-05-14 — — US disclosed
WO-2009059030-A1 PYRAZOLE DERIVATIVES AS KINASE INHIBITORS BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2009-05-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124621-A1 PYRAZOLE DERIVATIVES AS KINASE INHIBITORS BRAF, MAP3K1, MAP3K3 TDP1 1233/4885HSP90AA1 2124/4885ATM 221/4885
US-20110212961-A1 Pyrazole Derivatives as Kinase Inhibitors BRAF, MAP3K1, MAP3K3 TDP1 1233/4885HSP90AA1 2124/4885ATM 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback